Explore
Validate
Learn
Western blot
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [2]
- Immunocytochemistry [1]
- Immunohistochemistry [5]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-25690 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CDKN3 Monoclonal Antibody (OTI2E11)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- OTI2E11
- Vial size
- 100 µL
- Concentration
- 0.56 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Downregulated genes by silencing MYC pathway identified with RNA-SEQ analysis as potential prognostic biomarkers in gastric adenocarcinoma.
Heitor da Silva Maués J, Ferreira Ribeiro H, de Maria Maués Sacramento R, Maia de Sousa R, Pereira de Tommaso R, Dourado Kovacs Machado Costa B, Cardoso Soares P, Pimentel Assumpção P, de Fátima Aquino Moreira-Nunes C, Mário Rodriguez Burbano R
Aging 2020 Dec 22;12(24):24651-24670
Aging 2020 Dec 22;12(24):24651-24670
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of CDKN3 in HEK293T cells in untransfected (Left lane) and transfected (Right lane) samples using 5 µg per lane. The samples were separated by SDS-PAGE and probed with CDKN3 (Product # MA5-25690) monoclonal antibody.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of CDKN3 in A549, Jurkat cells using 10 µg per lane. Samples were probed with CDKN3 (Product # MA5-25690) monoclonal antibody at a dilution of 1:200.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of CDKN3 in COS7 cells. Cells were transfected with a plasmid overexpressing CDKN3 and probed with a CDKN3 monoclonal antibody (Product # MA5-25690).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry was performed on paraffin-embedded adenocarcinoma of human endometrium tissue. To expose target proteins, 10mM citric buffer, pH6.0, 100°C for 10min was used. Following antigen retrieval, tissues were probed with a CDKN3 monoclonal antibody (Product # MA5-25690).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry was performed on paraffin-embedded human prostate tissue. To expose target proteins, 10mM citric buffer, pH6.0, 100°C for 10min was used. Following antigen retrieval, tissues were probed with a CDKN3 monoclonal antibody (Product # MA5-25690).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry was performed on paraffin-embedded human kidney tissue. To expose target proteins, 10mM citric buffer, pH6.0, 100°C for 10min was used. Following antigen retrieval, tissues were probed with a CDKN3 monoclonal antibody (Product # MA5-25690).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry was performed on paraffin-embedded carcinoma of human bladder tissue. To expose target proteins, 10mM citric buffer, pH6.0, 100°C for 10min was used. Following antigen retrieval, tissues were probed with a CDKN3 monoclonal antibody (Product # MA5-25690).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry was performed on paraffin-embedded human endometrium tissue. To expose target proteins, 10mM citric buffer, pH6.0, 100°C for 10min was used. Following antigen retrieval, tissues were probed with a CDKN3 monoclonal antibody (Product # MA5-25690).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 Analysis of protein expression and immunohistochemistry in gastric cancer subtypes. ( A ) Representative image of Western-blot. Line 1 represents normal gastric tissue and the intensity of the genes are similar to early TNM stages and without metastasis, but much lower than advanced TNM stages (T3/T4). Initial stages with metastasis also have an intensity much higher than that of normal gastric tissue. ( B ) Positive TTLL12 cytoplasmatic immunostaining in diffuse-type gastric cancer (case 66 T2N3M1); ( C ) Positive CDC16 cytoplasmic and nuclear immunostaining in diffuse-type gastric cancer (case 140 T3N3M0); ( D ) Positive CDKN3 cytoplasmatic immunostaining in diffuse-type gastric cancer (case 203 T4N2M1); ( E ) Positive PTPRA cytoplasmatic immunostaining in intestinal-type gastric cancer (case 5 T1N0M0); ( F ) Positive MZT2B cytoplasmatic immunostaining in intestinal-type gastric cancer (case 61 T2N3M0); ( G ) Positive UBE2T cytoplasmatic and nuclear immunostaining in intestinal-type gastric cancer (case 149 T3N3M1) (magnification x40). The differences in band intensity and intensity of immunoreactivity are due to the different stages of TNM in tumor samples of diffuse and intestinal histological types that represent figures ( 3A , 3B - 3G ). ( H and I ) The function of the DEGs in the gastric lines showed a strong correlation between the increased level of protein expression with the human stomach cells in the data from The Human Protein Atlas (HPA) that were acces
